{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human&page=28",
    "query": {
      "condition": "Human",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 8247,
    "total_pages": 825,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Human&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T00:25:46.268Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001113",
      "title": "A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma, Kaposi",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Interferon alfa-n1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": null,
      "completion_date": "1990-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001113"
    },
    {
      "nct_id": "NCT00454220",
      "title": "Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multinodular Goiter"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "MRrhTSH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 96,
      "start_date": "2007-07",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454220"
    },
    {
      "nct_id": "NCT02663362",
      "title": "Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Body Composition",
        "Human Body Function"
      ],
      "interventions": [
        {
          "name": "To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "AdventHealth Translational Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "12 Years to 89 Years"
      },
      "enrollment_count": 250,
      "start_date": "2012-02",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663362"
    },
    {
      "nct_id": "NCT04915768",
      "title": "Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CH505 TF chTrimer",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-05-AF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum hydroxide suspension",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 51,
      "start_date": "2023-01-23",
      "completion_date": "2025-07-15",
      "has_results": true,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04915768"
    },
    {
      "nct_id": "NCT00055497",
      "title": "Remission in Subjects With Crohn's Disease, 1 Year Phase",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Double-blind (DB) adalimumab placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DB adalimumab 40 mg eow",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DB adalimumab 40 mg ew",
          "type": "BIOLOGICAL"
        },
        {
          "name": "OL adalimumab 40 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 276,
      "start_date": "2002-08",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2011-04-11",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 43,
      "location_summary": "Berkeley, California • Long Beach, California • San Diego, California + 36 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Weston",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055497"
    },
    {
      "nct_id": "NCT03520660",
      "title": "People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Hepatitis C, Chronic",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Epclusa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 121,
      "start_date": "2018-10-19",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520660"
    },
    {
      "nct_id": "NCT06058390",
      "title": "A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Bepirovirsen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 160,
      "start_date": "2023-10-04",
      "completion_date": "2024-05-03",
      "has_results": true,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 2,
      "location_summary": "Las Vegas, Nevada • Austin, Texas",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06058390"
    },
    {
      "nct_id": "NCT07348276",
      "title": "First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Progressive Supranuclear Palsy (PSP)",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "[18F]ABBV-964i",
          "type": "DRUG"
        },
        {
          "name": "[18F]ABBV-965i",
          "type": "DRUG"
        },
        {
          "name": "Lead Candidate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Invicro",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 11,
      "start_date": "2025-11-17",
      "completion_date": "2026-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07348276"
    },
    {
      "nct_id": "NCT06333496",
      "title": "Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Sugar; High",
        "Overweight and Obesity",
        "Fat Burn",
        "Obesity",
        "Heart Health Markers"
      ],
      "interventions": [
        {
          "name": "GLP-1 Booster (GB)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Alpine Biotech LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-01-02",
      "completion_date": "2024-05-08",
      "has_results": false,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06333496"
    },
    {
      "nct_id": "NCT03451162",
      "title": "Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "DHES0815A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-04-17",
      "completion_date": "2021-07-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-05",
      "last_synced_at": "2026-10-29T00:25:46.268Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03451162"
    }
  ]
}